Prothionamide

Prothionamide is an orally active thioamide antibacterial agent. Prothionamide is a substrate of OCT1 with a Km value of 805.8 μM. Prothionamide reacts with NAD to form a covalent adduct, with the adduct being a tight-binding inhibitor of Mycobacterium tuberculosis and Mycobacterium leprae InhA. Prothionamide can effectively inhibit the growth of Mycobacterium tuberculosis (MIC = ~0.5 µg/mL) and Mycobacterium leprae. Prothionamide is used in the research of tuberculosis and leprosy[1][2][3][4][5].

Product Specifications

CAS Number

[14222-60-7]

Product Name Alternative

Protionamide

UNSPSC

12352005

Hazard Statement

H302

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

Neuroscience-Neuromodulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/prothionamide.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

S=C(C1=CC(CCC)=NC=C1)N

Molecular Formula

C9H12N2S

Molecular Weight

180.28

Precautions

H302

References & Citations

[1]Wang F, et al. Mechanism of thioamide drug action against tuberculosis and leprosy.J Exp Med. 2007 Jan 22;204 (1) :73-8.|[2]Fajardo TT, et al. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am J Trop Med Hyg. 2006 Mar;74 (3) :457-61.|[3]Parvez MM, et al. Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters In Vitro. Antimicrob Agents Chemother. 2018 Aug 27;62 (9) :e00512-18.|[4]Grosset , et al. The role of low dosage prothionamide with and without 4, 4'-diaminio dipheimyl sulphone for use with isoniazld in the treatment of experimental mouse tuberculosis. Tubercle, 1982, 63 (1) : 37-43.|[5]Krasavin M, et al. Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis. Eur J Med Chem. 2018 Sep 5;157:1115-1126.